David Amsellem
Stock Analyst at Piper Sandler
(4.75)
# 131
Out of 5,182 analysts
174
Total ratings
65%
Success rate
21.71%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OGN Organon & Co. | Upgrades: Neutral | $5 → $14 | $13.24 | +5.78% | 7 | Apr 28, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $299 → $294 | $198.51 | +48.10% | 5 | Apr 23, 2026 | |
| BIIB Biogen | Upgrades: Overweight | $177 → $214 | $182.34 | +17.37% | 5 | Apr 14, 2026 | |
| DFTX Definium Therapeutics | Initiates: Overweight | $49 | $21.24 | +130.70% | 1 | Apr 10, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $45 → $43 | $33.91 | +26.81% | 9 | Mar 24, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $219 → $232 | $201.67 | +15.04% | 16 | Mar 19, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterates: Overweight | $40 → $41 | $31.49 | +30.20% | 12 | Mar 4, 2026 | |
| PTHS Pelthos Therapeutics | Initiates: Overweight | $48 | $24.77 | +93.78% | 1 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | $66 → $75 | $58.27 | +28.71% | 3 | Feb 23, 2026 | |
| AMGN Amgen | Maintains: Overweight | $381 → $432 | $342.04 | +26.30% | 7 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $12 | $14.76 | -18.67% | 8 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $148 → $223 | $187.37 | +19.02% | 4 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.93 | +159.93% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.95 | +361.54% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $8 | $4.15 | +93.00% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $6.06 | +32.12% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $12.66 | +2.69% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $129.51 | +38.21% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $48.78 | +33.25% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $21.67 | +15.37% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $47.04 | +157.23% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $33.04 | +12.00% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $9 | $9.60 | -6.25% | 3 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $79.20 | -14.14% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.74 | -47.69% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $25.41 | +65.29% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.98 | +428.30% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $31.00 | +35.48% | 3 | Oct 16, 2023 |
Organon & Co.
Apr 28, 2026
Upgrades: Neutral
Price Target: $5 → $14
Current: $13.24
Upside: +5.78%
AbbVie
Apr 23, 2026
Maintains: Overweight
Price Target: $299 → $294
Current: $198.51
Upside: +48.10%
Biogen
Apr 14, 2026
Upgrades: Overweight
Price Target: $177 → $214
Current: $182.34
Upside: +17.37%
Definium Therapeutics
Apr 10, 2026
Initiates: Overweight
Price Target: $49
Current: $21.24
Upside: +130.70%
Alkermes
Mar 24, 2026
Maintains: Overweight
Price Target: $45 → $43
Current: $33.91
Upside: +26.81%
Jazz Pharmaceuticals
Mar 19, 2026
Maintains: Overweight
Price Target: $219 → $232
Current: $201.67
Upside: +15.04%
Teva Pharmaceutical Industries
Mar 4, 2026
Reiterates: Overweight
Price Target: $40 → $41
Current: $31.49
Upside: +30.20%
Pelthos Therapeutics
Feb 27, 2026
Initiates: Overweight
Price Target: $48
Current: $24.77
Upside: +93.78%
Bristol-Myers Squibb Company
Feb 23, 2026
Maintains: Overweight
Price Target: $66 → $75
Current: $58.27
Upside: +28.71%
Amgen
Feb 18, 2026
Maintains: Overweight
Price Target: $381 → $432
Current: $342.04
Upside: +26.30%
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $14.76
Upside: -18.67%
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $187.37
Upside: +19.02%
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $6.93
Upside: +159.93%
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $1.95
Upside: +361.54%
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.15
Upside: +93.00%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $6.06
Upside: +32.12%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $12.66
Upside: +2.69%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $129.51
Upside: +38.21%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $48.78
Upside: +33.25%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $21.67
Upside: +15.37%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $47.04
Upside: +157.23%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $33.04
Upside: +12.00%
Mar 21, 2025
Downgrades: Neutral
Price Target: $15 → $9
Current: $9.60
Upside: -6.25%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $79.20
Upside: -14.14%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.74
Upside: -47.69%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $25.41
Upside: +65.29%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.98
Upside: +428.30%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $31.00
Upside: +35.48%